

Title (en)

TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES

Title (de)

TAUROLIDINBEHANDLUNG FÜR MYC-EXPRIMIERENDE TUMORE IN SÄUGETIERKÖRPERN

Title (fr)

TRAITEMENT À LA TAUROLIDINE POUR DES TUMEURS EXPRIMANT DES GÈNES MYC DANS DES CORPS DE MAMMIFÈRE

Publication

EP 3843747 A4 20221228 (EN)

Application

EP 19854097 A 20190903

Priority

- US 201862725650 P 20180831
- US 2019049266 W 20190903

Abstract (en)

[origin: WO2020047530A1] A method for treating a cancer which overexpresses any of N-myc genes, C-myc genes and/or L-myc genes in a mammalian body, the method comprising : administering a composition to the mammalian body, wherein the composition comprises at least one from the group consisting of taurolidine; taurultam; taurinamide; methylene glycol; taurultam and taurinamide in a ratio of 1 taurultam:7 taurinamide; and taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam:7 taurinamide:1 methylene glycol.

IPC 8 full level

A61K 31/549 (2006.01); **A61K 9/50** (2006.01); **A61K 38/19** (2006.01)

CPC (source: EP KR)

A61K 9/0019 (2013.01 - EP KR); **A61K 9/5123** (2013.01 - KR); **A61K 9/5146** (2013.01 - KR); **A61K 31/18** (2013.01 - EP KR); **A61K 31/549** (2013.01 - EP KR); **A61K 45/06** (2013.01 - EP KR); **A61K 47/10** (2013.01 - EP KR); **A61P 35/00** (2017.12 - KR); **A61K 2300/00** (2013.01 - KR)

Citation (search report)

- [XAI] US 2008171738 A1 20080717 - REDMOND H PAUL [IR], et al
- [XAI] US 2004176360 A1 20040909 - CALABRESI PAUL [US], et al
- [XAI] WO 0139762 A2 20010607 - RHODE ISLAND HOSP LIFESPAN PTR [US], et al
- [XAI] WO 2017158570 A1 20170921 - GEISTLICH PHARMA AG [CH]
- [XAY] WO 2007077528 A1 20070712 - GEISTLICH SOEHNE AG [CH], et al
- [XAY] MÖHLER HANS ET AL: "Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (Review)", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 45, no. 4, 1 October 2014 (2014-10-01), GR, pages 1329 - 1336, XP055945228, ISSN: 1019-6439, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151817/pdf/ijo-45-04-1329.pdf> DOI: 10.3892/ijo.2014.2566
- [XAYI] ANONYMOUS: "Cormedix Inc. announces agreement with nanoproteagen for its proprietary nanoparticle technology, Nanopro TM, in combination with CRMD-005 for pediatric neuroblastoma", INTERNET CITATION, 11 May 2016 (2016-05-11), XP002792142, Retrieved from the Internet <URL:http://www.cormedix.com/cormedix-inc-announces-agreement-with-nanoproteagen-for-its-proprietary-nanoparticle-technology-nanopro-in-combination-with-crmd-005-for-pediatric-neuroblastoma-2/> [retrieved on 20190617]
- [YA] STENDEL RUEDIGER ET AL: "Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Taurultame and Taurinamide in Glioblastoma Patients .", CLINICAL PHARMACOKINETICS., vol. 46, no. 6, 1 January 2007 (2007-01-01), NZ, pages 513 - 524, XP055945305, ISSN: 0312-5963, Retrieved from the Internet <URL:http://dx.doi.org/10.2165/00003088-200746060-00005> DOI: 10.2165/00003088-200746060-00005
- [Y] ANGERER JÜRGEN ET AL: "Opinion on methylene glycol", 26 June 2012 (2012-06-26), pages 1 - 14, XP055982131, Retrieved from the Internet <URL:chrome-extension://efaidnbmnnnibpccjpcglclefindmkaj/https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/scs_o_097.pdf> [retrieved on 20221116]
- [Y] LUO JUHUA ET AL: "Association between Six Environmental Chemicals and Lung Cancer Incidence in the United States", JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH, vol. 2011, no. 9, 1 January 2011 (2011-01-01), pages 1 - 9, XP055982102, ISSN: 1687-9805, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/jep/2011/463701.pdf> DOI: 10.1155/2011/463701
- [Y] KEVIN MARLEY ET AL: "Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, vol. 32, no. 1, 11 October 2013 (2013-10-11), pages 74, XP021165358, ISSN: 1756-9966, DOI: 10.1186/1756-9966-32-74
- [A] JONES D S ET AL: "A study of the stability of taurolidine in plasma and protein-free serum", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 64, no. 2-3, 30 October 1990 (1990-10-30), pages R1 - R4, XP023736496, ISSN: 0378-5173, [retrieved on 19901030], DOI: 10.1016/0378-5173(90)90278-C
- See references of WO 2020047530A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2020047530 A1 20200305; AU 2019331913 A1 20210429; CA 3111100 A1 20200305; CN 113226325 A 20210806; EP 3843747 A1 20210707; EP 3843747 A4 20221228; JP 2021535167 A 20211216; KR 20210054544 A 20210513

DOCDB simple family (application)

US 2019049266 W 20190903; AU 2019331913 A 20190903; CA 3111100 A 20190903; CN 201980072806 A 20190903; EP 19854097 A 20190903; JP 2021511591 A 20190903; KR 20217009412 A 20190903